Trials / Completed
CompletedNCT01717248
Safety Study of GCS-100 to Treat Chronic Kidney Disease
A Phase 1 Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- La Jolla Pharmaceutical Company · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety of GCS-100 as a treatment for chronic kidney disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GCS-100 | GCS-100 is a modified citrus pectin that binds to and sequesteres circulating galectin-3, a protein that has been shown to promote organ disease (fibrosis). |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2013-06-01
- Completion
- 2013-06-01
- First posted
- 2012-10-30
- Last updated
- 2013-06-20
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01717248. Inclusion in this directory is not an endorsement.